GR2303 injection safety and immune response in healthy adults
Official title: A Randomized, Double-blind, Placebo-controlled of GR2303 Injection in Healthy Adult Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacologic of GR2303
Run by Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT07199270 · Data updated 2026-11-12
This trial will try GR2303 injections in healthy adults to see if they are safe and how the body handles them and responds immunologically.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Enrollment | 64 (estimated) |
| Sponsor | Genrix (Shanghai) Biopharmaceutical Co., Ltd. Industry-sponsored |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | September 18, 2025 |
| Main results expected | September 18, 2026 |
| Study ends | December 16, 2026 |
| Registry record updated | September 30, 2025 |
| Trial ID | NCT07199270 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults who can give informed consent, pass screening exams and labs, and have no significant organ disease or prior use of TNF-like cytokine 1A–targeting drugs are eligible.
✕Probably not a fit
People with active inflammatory disease seeking therapy, a history of malignancy, positive hepatitis B/C or HIV tests, significant organ disease, or prior exposure to TNF-like cytokine 1A–targeting therapies are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, double-blind, placebo-controlled Phase 1 trial enrolls healthy adult Chinese volunteers into sequential cohorts. Within each cohort, participants are randomly assigned to receive either GR2303 injection or placebo, and each participant is enrolled in only one group. The study collects safety data, tolerability assessments, pharmacokinetic sampling, and immunogenicity testing over scheduled visits. Findings will inform dosing and further clinical development for inflammatory conditions.
Why it matters
Potential benefit: If successful, GR2303 could become a new immune-targeting treatment option for inflammatory conditions such as inflammatory bowel disease.
How similar studies have gone: Other biologics targeting related inflammatory cytokines have shown promise in later-stage trials, but GR2303 is a novel agent undergoing early human testing.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Healthy adult subjects 2. Signed informed consent Exclusion Criteria: 1. History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects. 2. Prior use of drug targeting TNF-like cytokine 1A 3. history of malignant tumor 4. psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)
Where it's running
-
Beijing Friendship hospital, Capital Medical University
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Nian
- Email: nianhanli@genrixbio.com
- Phone: 021-50805989-08324
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Morningness vs. eveningness and how quickly healthy adults recover after submaximal exercise
This study tests whether people who prefer morning or evening are linked to how quickly healthy adults recover after a light-to-moderate workout.
-
Orally Taken TIX100 in Healthy Overweight/Obese Adults
This study will test whether daily oral TIX100 is safe and well tolerated in healthy adults who are overweight or obese.
-
YR001 Topical Ointment safety and PK in healthy Chinese adults
This study tests whether YR001 ointment is safe and tolerable and how it behaves in the body after single and repeated applications in healthy Chinese adults, compared with a placebo.
-
Does Yoga Style Affect Sleep and Heart Health in Adults with and without Insomnia
This study tests whether two styles of yoga (vinyasa and gentle yoga) done in the evening can improve sleep and heart health in adults, including those with insomnia.
-
Single-dose testing of JPH034 in healthy adults.
This trial tests single ascending doses of the experimental drug JPH034 versus placebo in healthy adults aged 18–50 to see if the drug is safe, how the body handles it, and whether food affects absorption.
-
Muscle–brain connections in older adults with and without neurological disorders
See if muscle–brain connections differ between healthy adults aged 60+ and people over 60 who have neurological disorders such as ALS, Parkinson's, Alzheimer's, or severe acquired brain injury.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.